OPT רווח למניה בשנים עשר החודשים האחרונים Opthea Ltd.

Massive demand for macular degeneration therapy is being constrained by uncertainty surrounding final drug trials, creating risks for capitalization. The TTM EPS dynamics for Opthea Limited (OPT) are recorded at -2.33 on this GURU.Markets platform chart. Business stability is ensured by competent Australian management, which demonstrates full research transparency and an ability to attract global partners in ophthalmology.

For Opthea Limited (OPT), EPS becomes a key indicator of capitalization efficiency amid fierce competition with ophthalmology giants. This metric is calculated by dividing the total annual net income by the total number of shares. By analyzing the EPS trend over the last 12 months, an investor assesses the real return on each share of ownership. This price action reflects the company's ability to generate profit despite pressure from blockbuster competitors. Steady growth confirms the viability of the business model.